Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Clinical trial NCT06956001 · RECRUITING

Trial details

NCT number: NCT06956001
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

EGFR NSCLC (Advanced Non-small Cell Lung Cancer)

Start date: 2024-11-19
Primary completion: 2027-12-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.